Who are Bepotastine besilate formulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): fexofenadine HCl, Olopatadine Nasal Spray, Morphine-Promethazine, Azelastine - intranasal application, Hydroxyzine HCL, Fluticasone/Azelastine nasal spray.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bepotastine-besilate-formulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bepotastine besilate formulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bepotastine besilate formulation (Bepotastine besilate formulation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist. Area: Ophthalmology / Allergy.

phase 3 H1-receptor antagonist H1 histamine receptor Ophthalmology / Allergy Small molecule Live · refreshed every 30 min

Target snapshot

Bepotastine besilate formulation (Bepotastine besilate formulation) — Bausch & Lomb Incorporated. Bepotastine besilate is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bepotastine besilate formulation TARGET	Bepotastine besilate formulation	Bausch & Lomb Incorporated	phase 3	H1-receptor antagonist	H1 histamine receptor
fexofenadine HCl	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
Azelastine - intranasal application	Azelastine - intranasal application	Association Asthma, Bulgaria	marketed	Selective H1-receptor antagonist (intranasal antihistamine)	H1 histamine receptor
Hydroxyzine HCL	Hydroxyzine HCL	National Cancer Institute (NCI)	marketed	First-generation H1 antihistamine	H1 histamine receptor
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist class)

Allergan · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Faes Farma, S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bepotastine besilate formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/bepotastine-besilate-formulation. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab